BioNTech


Management focus is on a strong balance sheet

20/11/23 -"After the fairly decent Q3 results and the guidance cut on costs, a mix of lower operating costs, higher interest income (again) and a lower tax rate have all driven an upgrade to our 2023 EPS ..."

Pages
52
Language
English
Published on
20/11/23
You may also be interested by these reports :
07/12/23
Sanofi has unveiled its R&D plans today in an effort to convince investors of their effectiveness, as the share price hasn’t yet fully recovered ...

05/12/23
With the >$3bn Carmot Therapeutics acquisition, Roche has entered the race in the burgeoning anti-obesity market. While, against the backdrop of ...

05/12/23
Takeaways from our third & fourth Materials Reverse Roadshow Day with Sika, Siegfried, Wacker and Bucher

04/12/23
Bayer (Buy, Germany) has entered the Alphavalue top 20 chart of companies with the strongest upsides. Being number 12 in this hit parade, the company ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO